Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...

In an effort to boost global biopharma competitiveness, the U.K.’s National Institute for Health and Care Research (NIHR) has ...

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.

Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate. | Bayer has discontinued an early-stage clinical gene therapy for a rare ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Nvidia, the computer chip giant, continues its deep dive into expanding artificial intelligence technology in the medtech and cancer research arenas, this time with diagnostics maker Droplet ...

U.S.-based RadNet is paying 215 million euros upfront, with another 15 million euros on the table tied to future milestones. RadNet plans to merge Gleamer with its 2020 DeepHealth buy, its artificial ...

Medimaps markets AI-driven bone microarchitecture imaging technologies such as TBS Osteo and TBS Reveal, which assess ...

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...